Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 213 participants.

Also called NCT03006770

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 213 participants (enrolled count) (from the registry)
Sponsor
Pluristem Ltd. (from the registry)
Registry
  • NCT NCT03006770
Other papers using this trial's data
  • PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial The British journal of surgery, 2024-01-31 DOI, PubMed 38294084, PMC10828925 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Bulgaria, Czechia, Germany, Hungary, Israel, North Macedonia, Poland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03006770. Randomized; double masking; primary purpose treatment. Start 2017-05-22 (actual); primary completion 2021-03-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
Condition
Critical Limb Ischemia (CLI)
Intervention (Biological)
PLX-PAD
Intervention (Biological)
Placebo
Lead sponsor
Pluristem Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03006770
Content hash
546f28b55fe629416d2f76b7c1ef90a145b85ec13e6ad95239af260b4ae31ca7